↓ Skip to main content

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Overview of attention for article published in BMC Cancer, January 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

blogs
1 blog
twitter
10 X users

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
70 Mendeley